Clinical Manifestations of Elevated Testosterone in a 55-Year-Old Woman
Elevated testosterone in a 55-year-old postmenopausal woman causes cutaneous manifestations (hirsutism, acne, androgenic alopecia), reproductive dysfunction, metabolic complications (insulin resistance, dyslipidemia, hypertension), and in severe cases, virilization with clitoral hypertrophy and voice deepening 1.
Cutaneous and Dermatologic Manifestations
The pilosebaceous unit (PSU) responds directly to androgen excess, producing the most visible clinical signs:
Hirsutism: Excessive terminal hair growth on the lower back, sternum, abdomen, shoulders, buttocks, and inner thighs. The Ferriman-Gallwey scale quantifies severity and tracks treatment response 1. Rapid onset hirsutism, particularly in a postmenopausal woman, should raise immediate suspicion for an androgen-secreting tumor (ovarian or adrenal) 1.
Androgenic Alopecia: Hair loss typically begins at the vertex and crown, progressing to diffuse thinning. With severe hyperandrogenemia, male-pattern baldness with bitemporal recession occurs, often accompanied by clitorimegaly and amenorrhea 1, 2, 3.
Acne: Persistent or treatment-resistant acne in a postmenopausal woman indicates hyperandrogenism requiring investigation 1.
Critical Pitfall: The severity of cutaneous manifestations does not correlate with testosterone levels due to variable PSU sensitivity to androgens and ethnic/genetic differences in 5α-reductase activity 1. A woman may have markedly elevated testosterone without appreciable hirsutism.
Virilization (Severe Hyperandrogenemia)
When testosterone levels are very high (typically >2-3 SD above normal), virilization occurs 1:
- Clitoral hypertrophy
- Voice deepening (irreversible)
- Androgenic muscle development
- Breast atrophy
- Male-pattern baldness
- Masculine body habitus
A rapidly progressing virilization syndrome in a postmenopausal woman demands urgent evaluation for androgen-secreting tumors (ovarian Leydig cell tumor, steroid cell tumor, hyperthecosis, or adrenal neoplasm) 1, 2, 4.
Reproductive and Menstrual Effects
In a 55-year-old postmenopausal woman, the reproductive manifestations differ from younger women:
- Suppressed gonadotropins: Elevated testosterone inappropriately suppresses FSH and LH, which should be elevated in menopause 4.
- Detectable estradiol: Peripheral aromatization of excess androgens produces measurable estradiol despite ovarian senescence 2.
- Increased libido: May occur with testosterone excess 3.
Metabolic and Cardiovascular Complications
The most clinically significant long-term consequences affect morbidity and mortality 1:
Insulin Resistance: Hyperandrogenism drives insulin resistance independent of obesity. Fasting glucose-to-insulin ratio <4.5 indicates insulin resistance 1.
Dyslipidemia: Reduced HDL cholesterol and elevated triglycerides increase atherosclerotic cardiovascular risk 1.
Hypertension: Frequently associated with hyperandrogenemia and may improve after androgen source removal 1, 4.
Impaired Glucose Tolerance/Type 2 Diabetes: Present in 40-45% of hyperandrogenic women at initial evaluation 1.
Polycythemia: Elevated red blood cell counts occur with severe testosterone excess 4.
These metabolic abnormalities place patients at substantially increased risk for cardiovascular disease and should be the primary therapeutic concern, even when cutaneous symptoms are the presenting complaint 1.
Diagnostic Algorithm for a 55-Year-Old Woman
When evaluating elevated testosterone in this age group:
Measure total testosterone by liquid chromatography-tandem mass spectrometry (LC-MS/MS), not immunoassay, as immunoassays lack accuracy at female testosterone ranges 5, 2.
Assess rapidity of onset: Rapid progression over months suggests neoplasm; gradual onset over years suggests functional hyperandrogenism 1.
Check DHEAS and androstenedione: Normal levels suggest ovarian source; elevated DHEAS suggests adrenal source 2.
Evaluate gonadotropins: Suppressed FSH/LH in a postmenopausal woman with elevated testosterone is inappropriate and suggests autonomous androgen production 2, 4.
Imaging: Transvaginal ultrasound and CT abdomen/pelvis to identify ovarian or adrenal masses. However, ovarian hyperthecosis and hilus cell hyperplasia may not be visible on imaging 2, 3, 6.
GnRH analog stimulation test: If testosterone normalizes within 4 weeks, confirms ovarian source 2.
Source-Specific Etiologies in Postmenopausal Women
The differential diagnosis in a 55-year-old woman differs substantially from reproductive-age women:
- Ovarian hyperthecosis: Most common functional cause; bilateral ovarian stromal luteinization without discrete tumor 1, 2, 3
- Ovarian tumors: Leydig cell tumor, steroid cell tumor (rare, <0.1% of ovarian neoplasms) 4, 7
- Ectopic adrenal tissue: Adrenal rests in ovarian/periovarian tissue with adenomatous change 6
- Adrenal tumors or CAH: Less common in this age group 1
Important caveat: Histopathologic diagnosis often requires surgical excision, as imaging may be normal despite significant androgen-secreting pathology 2, 3, 6.